Blog

Proving The Work We Do Is Good For the World - $1.4Billiion Settlement Related to Opioid Epidemic

Posted by Audrey Schechter | Jul 12, 2019 | 0 Comments

Yesterday, the Department of Justice announced a $1.4 Billion settlement against global consumer conglomerate Reckitt Benckiser Group plc to resolve potential criminal and civil liability related to a federal investigation of the marketing of the opioid addiction treatment drug Suboxone. The resolution – the largest recovery by the United States in a case concerning an opioid drug – includes the forfeiture of proceeds totaling $647 million, civil settlements with the federal government and the states totaling $700 million, and an administrative resolution with the Federal Trade Commission for $50 million.

From the DOJ press release:

Under the civil settlement, RB Group has agreed to pay a total of $700 million to resolve claims that the marketing of Suboxone caused false claims to be submitted to government health care programs. The $700 million settlement amount includes $500 million to the federal government and up to $200 million to states that opt to participate in the agreement. The claims settled by the civil agreement are allegations only and there has been no determination of liability.

The civil settlement addresses allegations by the United States that, from 2010 through 2014, RB Group directly or through its subsidiaries knowingly: (a) promoted the sale and use of Suboxone to physicians who were writing prescriptions without any counseling or psychosocial support and for uses that were unsafe, ineffective, and medically unnecessary and that were often diverted for uses that lacked a legitimate medical purpose; (b) promoted the sale or use of Suboxone Film to physicians and state Medicaid agencies using false and misleading claims that Suboxone Film was less susceptible to diversion and abuse than other buprenorphine products and that Suboxone Film was less susceptible to accidental pediatric exposure than tablets; and (c) submitted a petition to the Food and Drug Administration on Sept. 25, 2012, claiming that Suboxone Tablet had been discontinued “due to safety concerns” about the tablet formulation of the drug and took other steps to delay the entry of generic competition for Suboxone in order to improperly control pricing of Suboxone, including pricing to federal healthcare programs.

For the full press release, click here.

About the Author

Audrey Schechter

Audrey Hildes Schechter is an experienced commercial and civil litigator, working in the areas of fraud, qui tam, healthcare fraud, Medicare and Medicaid fraud, Tricare fraud, appellate practice, health care law, and employment litigation. Audrey has practiced in Florida for 25 years and in New Y...

Comments

There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment

Contact Us

If you want to report fraud against the government but you are concerned about your future, we are here to help. We will help protect your rights as a whistleblower to obtain the reward you deserve. Contact the Schechter Legal Group today.

Menu